Table 2 Radiation doses for patients with conventional salvage radiotherapy (C-SRT) and those with 18F-rhPSMA-7/18F-flotufolastat-guided salvage radiotherapy.

From: Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer

 

Patients with C-SRT

(n = 28)

Patients with 18F-rhPSMA-7/18F-flotufolastat-guided SRT

(n = 82)

Median (range) total dose in

EQD2(α/β = 1.5 Gy),

Gy

Median (range) total dose in EQD2(α/β = 1.5 Gy),

Gy

Prostate Bed

68.0 (60.0–68.0)

68.0 (64.5–70.0)

Elective pelvic lymph nodes

47.5 (44.0–50.0)

47.5 (47.5–47.5)

PET-positive lymph nodes

–

60.5 (60.5–68.0)

PET-positive local recurrence

–

82.0 (68.0–82.0)

  1. C-SRT, conventional salvage radiotherapy; EQD2, equivalent dose in 2 Gy fractions with an α/β ratio of 1.5 Gy; PET, positron emission tomography; SRT, salvage radiotherapy.
Back to article page